Cellex is a Germany-based end-to-end CDMO with extensive expertise in the development and GMP manufacturing of autologous and allogeneic cell and gene therapy (CGT) products. With a GMP track record of more than 20 years, Cellex supports partners from preclinical development through clinical manufacturing to commercialization, serving top 10 pharma companies, biotechs, innovative start-ups, and academic centers worldwide.

Cellex operates > 2,500 m² of GMP manufacturing space and holds multiple manufacturing licenses covering cellular intermediates and final drug products. The company is involved in manufacturing three approved CAR-T therapies and has produced over 9,500 CGT/ATMP batches.

Through its own apheresis center and donor database, Cellex has performed more than 50,000 cell collections for CGT and SCT and supplies GMP-compliant donor materials globally through validated, GDP-compliant transport solutions. EU QP services, consulting, and GMP audits complement Cellex’s offering, reflecting its scientific expertise, quality, and flexibility.